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A symposium entitled ‘‘Gene regulation and function
in health and diseases’’ took place in September in cel-
ebration of Richard Flavell’s 60th birthday and his con-
tribution to science.
A photograph of Richard Flavell was shown to pass-
ersby on the streets of New Haven, Connecticut. Despite
his flannel shirt and rather humble appearance, most
people thought he had the look of an intelligent man.
But, to Richard’s great disappointment, his photo did
not exude the image of a ‘‘rock star’’! (See Figure 1.) Hav-
ing had an inquisitive interest in music along with sci-
ence since childhood, Flavell is frequently invited to sci-
entific meetings either to give a keynote talk or to play
his guitar with the ‘‘Cellmates,’’ a rock band made up
of other renowned scientists Ira Mellman, Leonard
Kaczmarek, William Philbrick, and Flavell’s wife, Madlyn
Flavell.
Richard Anthony Flavell, born in the United Kingdom
in 1945, has lived a life unique to most scientists. Flavell
received his Bachelor of Science degree in 1967, and at
the age of 25, he received his Ph.D. for work on the DNA
of protozoa with Ian Gwyn Jones from the University of
Hull, Great Britain. He completed his post-doctoral train-
ings with Piet Borst in Amsterdam and Charles Weiss-
mann in Zurich and in 1974 established his independent
laboratory in the Department of Biochemistry at the Uni-
versity of Amsterdam. Today, although famous to the
younger scientists for his studies on the immune sys-
tem, Flavell is known to his peers for establishing the
first methodology for site-directed mutagenesis (Flavell
et al., 1974), expanding the use of Southern blotting to
analysis of mammalian DNA, and using this method to
demonstrate the existence of introns in mammalian
genes. His lab was the first to construct cosmid libraries
and used them to isolate the globin and MHC genes. In
1980, Flavell won the Colworth Medal for being the
most promising British biochemist under 35. At that
time, he already had a total of 52 publications, ten of
which were in Cell, Nature, or Science.
Returning to the United Kingdom in 1979, Flavell be-
came the head of the Laboratory of Gene Structure
and Expression at the National Institute for Medical Re-
search in Mill Hill, London. In 1982 Flavell became the
Vice President of R&D at Biogen Research Corporation
*Correspondence: cdong@mdanderson.orgin Cambridge, Massachusetts and, soon after, was pro-
moted to become the president and then the chief scien-
tific officer. After several years of corporate experience
and living the life of the Cellmates’ often-sung ‘‘Molecu-
lar Millionaire,’’ he returned to academia as an investiga-
tor of the Howard Hughes Medical Institute and as the
Chairperson and Professor of Immunobiology at Yale
University School of Medicine. He is also a member
of numerous learned societies, including the European
Organization of Molecular Biology, Royal Society in
London, and the National Academy of Sciences in the
United States.
On September 14 and 15, 2005, a symposium entitled
‘‘Gene Regulation and Function in Health and Diseases’’
was held at Yale University to celebrate Flavell’s 60th
birthday and to honor his many scientific contributions.
Flavell’s former mentors, trainees, and colleagues from
all over the world gathered in New Haven to share their
stories about Flavell and speak about their more recent
journey on a common path: understanding gene regula-
tion and function in health and disease.
Gene Regulation in Development
Flavell started his independent scientific career by
studying the structure and regulation of the globin
genes. Along with his first postdoctoral trainee, Sir Alec
Jeffreys (University of Leicester, UK), he resolved the
structure of the b globin gene. Not only was this the first
resolved mammalian gene structure, but it also demon-
strated the surprising presence of unknown noncoding
gene segments interspersed between the coding seg-
ments found in cDNA—we now know these segments
as introns (Jeffreys and Flavell, 1977). Flavell was only
several months behind Philip Sharp and his colleagues,
who documented the existence of introns in viral RNA,
which led them to the Nobel Prize in 1993. A few years
later, with another postdoctoral trainee, Meinrad Bus-
slinger (Research Institute of Molecular Pathology,
Vienna), he suggested a role for CpG methylation in neg-
ative regulation of gene expression (Busslinger et al.,
1983), which has since been shown to be a crucial epige-
netic mechanism for gene silencing in mammalian
genes.
Flavell’s early work and expertise in molecular biology
have nurtured the development of several world-
renowned molecular biologists who continue to be the
leaders in their own fields of study. Frank Grosveld
(Erasmus University, The Netherlands), Dimitris Kioussis
(National Institute for Medical Research, UK), and Mein-
rad Busslinger have continued to study the gene regula-
tion mechanisms during development of various line-
ages of hematopoietic cells, which occur in restricted
lymphoid organs. Precisely how stem cells differentiate
into precursors that initiate an environment that pro-
motes lymphogenesis is unclear. Kioussis described
a transgenic mouse model he constructed by placing
green fluorescent protein (GFP) coding sequence into
the CD2 gene cassette, which is specifically expressed
in T lineage cells. Unexpectedly, Kioussis found that
GFP was also expressed in E13.5 embryos by
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Littman (New York University, NY) has also character-
ized these cells, which he calls lymphoid tissue inducer
(LTi) cells. Littman was drawn to the field by his work on
RORgt, a nuclear hormone receptor important not only
for thymic development but also for lymph node organ-
ogenesis. Littman was able to visualize LTi cells by
inserting GFP into RORgt locus. These two lines of re-
porter mice are likely to provide a better understanding
of the mechanisms of gene regulation in the genesis of
the lymph node structure.
Continuing with the globin tradition started with Fla-
vell, F. Grosveld summarized his pioneering work in
understanding how the long-range globin locus is coor-
dinately regulated by locus control regions. He also pre-
sented elegant biochemical data on purification of com-
plexes containing erythroid specific GATA-1 and Ldb-1
transcription factors, which coupled with chromatin im-
munoprecipitation and promoter reporter analysis has
greatly assisted the understanding of the physiological
function of these lineage-specific transcription factors.
Busslinger discussed his studies of transcriptional
control of B lymphopoiesis. His laboratory has been
Figure 1. Richard Flavell—A Rocking Scientist
Courtesy of Harold Shapiro for the Howard Hughes Medical Institute.studying the role of Pax5, a B cell-specific transcription
factor. He drew upon his earlier studies, which demon-
strated that when newly committed B cells lose Pax5
gene expression, they redifferentiate into myeloid cells.
In the symposium, Busslinger showed new data indicat-
ing that Pax5 is required to maintain B cell specification
even in late mature B cells. Mature B cells, after deletion
of the Pax5 gene, are capable of differentiating into
T lymphocytes.
Flavell started on his path toward the study of immu-
nology at Mill Hill by analyzing the structure of MHC
genes. He continued this work at Biogen and applied
transgenic approaches toward understanding mech-
anisms of immune tolerance. Cheong-Hee Chang (In-
diana University, IN) presented data showing that en-
forced expression of CTIIA, a master regulator of the
MHC class II gene, on thymocytes induces these cells
to express MHC class II and self-select for CD4+ T cells.
This selection of CD4+ T cells proceeded in the absence
of class II expression by any other thymus cells, such as
epithelial cells or dendritic cells that are thought to be
the positive-selecting cells. Because human T cells are
known to express class II, this finding in the mouse
may allow a better understanding of the mechanisms
of human T cell development.
Max Cooper (University of Alabama, AL), who has
a long-term interest in tracing lymphocyte development
and identifying the origins of adaptive immunity, dis-
cussed his laboratory’s recent finding on rearranged
leucine-rich repeat encoding sequences to generate
variable lymphocyte receptors in sea lamprey. Because
Rag1 or Rag2 has not been identified in this jawless ver-
tebrate, further studies will likely unveil unique mecha-
nisms in the regulation of gene recombination and regu-
lation of lymphocyte-like cell development.
Innate Immunity Mechanisms
The innate immune responses are the first line of host
defense against invading pathogens. The importance
of innate immunity was largely ‘‘revived’’ by Flavell’s col-
league, the late Charles Janeway, Jr. along with Ruslan
Medzhitov (Yale Universtiy, CT), who discovered the first
Toll-like receptor (TLR) in mammalian cells. Flavell’s re-
search has led to the understanding of important mole-
cules such as IRAK-M, RICK, Nod2, and NALPs in the in-
nate immune system.
Antigen-presenting cells, such as dendritic cells (DCs),
that express TLRs are crucial components of the innate
immune response, and understanding the function and
regulation of different subsets of DCs has become a
recent challenge among immunologists. Plasmacytoid
dendritic cells (pDCs) are major producers of type I inter-
ferons in the anti-viral innate immune response. Yumiko
Kamogawa-Schifter (Ginkgo Biomedical Research Insti-
tute, Japan) used Ly49Q to identify pDCs and character-
ized them into two subsets. Ly49Q is a C-type lectin ex-
pressed on pDCs but not on myeloid DCs. Ly49Q+ pDCs
produce greater amounts of inflammatory cytokines
than Ly49Q2 pDCs. These results indicate that Ly49Q
could be a specific marker for peripheral pDCs and that
two distinct subsets of pDCs can be identified based
on the expression of Ly49Q in the bone marrow.
Tadatsugu Taniguchi (Tokyo University, Japan)
shared some postdoctoral days with Flavell in
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and IRF7 are important for TLR-initiated interferon pro-
duction. He also suggested that IRF4 might serve as
a negative regulator of TLR-induced interferon produc-
tion. Roel Nusse (Stanford University, CA) described
his recent work on WntD as a negative regulator of
NF-kB signaling and innate immunity in Drosophila. His
laboratory has shown that WntD acts as a feedback
inhibitor of the NF-kB homolog, Dorsal, during both em-
bryonic patterning and the innate immune response to
infection. These results describe the first secreted feed-
back antagonist of Toll signaling. It will be interesting to
examine whether this regulation is conserved in mam-
malian systems.
Transcription in T cells
Another research focus in the Flavell laboratory is under-
standing the molecular programs of helper T cell differ-
entiation, which led Flavell to elucidate the role of tran-
scription factors and MAP kinase pathways in this
process. These studies have now, in an interesting
turn of history, brought him back to his earlier gene
structure work. When studying the Th2 cytokine locus
(which encompasses the Il4, Il5, and Il13 genes), his
lab recently discovered the presence of a locus control
region, which physically interacts with and regulates
expression of all three cytokine genes in this locus. Un-
expectedly, it was found that this region also physically
interacts with a regulatory region in the Ifng gene on
a completely different chromosome, a finding with pos-
sible immunological implications for the coordinated
regulation of Th1 and Th2 genes as well as for the de-
velopment of chromosomal translocations involved in
cancer.
Whereas the Flavell laboratory characterized GATA-3
as the master regulator of Th2 cell differentiation and
function, Laurie Glimcher’s (Harvard University, MA) lab-
oratory was the first to identify and characterize the
T-bet transcription factor, which is the counterpart of
GATA3 in Th1 cells. Glimcher demonstrated that in addi-
tion to its crucial role in T helper differentiation, T-bet
has essential functions in B cells as well as in DCs. In ad-
dition, Glimcher showed data that indicate that T-bet is
crucial for immunity against lung infection and that the
lack of T-bet protects against autoimmunity. These
data suggest that T-bet may function as a master regu-
lator of Th1-type immunity.
In contrast to the effector Th1 cells that are often re-
sponsible for autoimmune diseases, a major role of
CD4+ regulatory T (Treg) cells is to maintain peripheral
tolerance and to inhibit autoimmunity. Discussing his
recent findings on these ‘‘suppressor’’ T cells, Alexander
Rudensky (University of Washington, WA) focused on
Treg’s signature transcription factor, Foxp3. Genetic
marking of these cells via a fluorescent reporter
knocked in the Foxp3 locus revealed neonatal days 3–
4 as a critical window for the production of Treg cells
in the thymus.
An understanding of the proper regulation of tran-
scription programs in T cells is important for under-
standing their effector function and provides insight
into how these cells maintain their normal physiology.
NFATc1 is a transcription factor that is important in early
T cell activation and Th2 differentiation. Edgar Serfling(University of Wuerzburg, Germany) showed that epige-
netic dysregulated NFATc1 expression is associated
with lymphoid malignancies.
Immune Tolerance and Autoimmunity
Members of the Flavell laboratory have been working to
understand the mechanisms of T cell tolerance and au-
toimmunity. In particular, they have demonstrated the
role of pro-inflammatory cytokine tumor necrosis factor
and anti-inflammatory cytokines Transforming growth
factor-b and IL-10 in the regulation of tolerance and au-
toimmune disease models.
Multiple immune-tolerance mechanisms were de-
scribed at the symposium. Andrew Mellor (Medical
College of Georgia, GA) identified a new interferon-
producing DC subset that is CD19+ but does not express
the pDC marker 120G8. Treatment of these cells with the
TLR9 ligand CpG oligodeoxynucleotides induces the ex-
pression of the immunoregulatory enzyme indoleamine
2,3-dioxygenase (IDO) and hence allowed these CD19+
DCs to acquire potent IDO-dependent T cell-suppres-
sive functions. In addition, Mellor showed that GCN2
kinase is a regulator of T cell tolerance. GCN2 kinase-
deficient T cells lose responsiveness to immunosup-
pression by IDO-producing DCs.
Anne O’Garra (National Institute for Medical Re-
search, UK), who has pioneered the study and charac-
terization of IL-10-expressing T cells, showed that these
T cells are distinct from naturally occurring Foxp3+ Treg
cells. These Foxp32, IL-10+ T cells can be generated by
an in vivo tolerance regime and represent another po-
tential avenue for treating autoimmune and inflamma-
tory diseases.
The failure of immune tolerance can result in autoim-
munity, the mechanisms of which are extensively stud-
ied by scientists worldwide. Allison Green’s (University
of Cambridge, UK) data suggest the presence of a po-
tential diabetes-susceptibility locus on chromosome 4
of NOD mice. Tom Aune (Vanderbilt University, TN) dis-
cussed his work to identify common gene-expression
patterns and dysregulated chromosomal clusters in hu-
man autoimmune diseases and emphasized the impor-
tance of this type of genomics approach in understand-
ing and treating human patients.
Understanding the mechanisms involved in the de-
velopment of disease can ultimately lead to effective
‘‘bench-to-bedside’’ therapeutic approaches. Together
with Erol Frikrig (Yale University, CT), Flavell discovered
the first vaccine against Lyme disease. Several speakers
discussed exciting new therapeutic approaches. Kei-
suke Kuida (Vertex, MA) showed caspase 1 inhibitors
to be a potent treatment for inflammatory diseases in
mouse models. Matthias von Herrath (La Jolla Institute
of Allergy and Immunology, CA) discussed novel strate-
gies to revert recent-onset diabetes by combining
a short-term immune suppression with anti-CD3- and
islet-antigen-specific immunization to induce Treg cells.
This approach should enhance efficacy while circum-
venting side effects for the treatment of autoimmune
diabetes.
Mechanism of Gene Regulation
Although understanding transcriptional and epigenetic
regulation of genomic DNA has kept many scientists
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gene-regulatory mechanisms have captured the atten-
tion of many in recent years. Phil Sharp (MIT, MA), who
was instrumental in recruiting Flavell to Biogen in the
‘80s, spoke about short RNAs. These RNA molecules,
including sRNA and microRNA, are new players in regu-
lating gene expression and are likely critical for cytokine
gene regulation in the immune system.
The symposium spanned several areas in which Ri-
chard Flavell has made significant scientific contribu-
tions. The scientific diversity demonstrates that Flavell’s
impact in science has reached well beyond his original
training as a molecular biologist. Kim Bottomly (Yale
University, CT) described the current status of the Sec-
tion of Immunobiology at Yale University as one of the
best and most exciting centers for immunology research
and training. Flavell, the only chair of the section in
history, has thus provided a crucial leadership role for
its development and advancement. In addition, as evi-
denced by the number of former trainees who partici-
pated in the symposium, Flavell has inspired many
talents, some of whom have become prominent scien-
tists themselves. As Andre Bernard (Massachusetts
General Hospital, MA) puts it, ‘‘Richard convinced me
and many others that a career in science might be fun
and worthwhile’’; Flavell taught us all that there is always
a new heaven in the study of gene regulation and func-
tion.
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